Pulse interleukin-2 with famotidine induces CD56+ lymphocytes in the peripheral blood of patients with metastatic melanoma or kidney cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 1, 2011, Pages 65-67

  Quan, Walter D Y ^a   Gagnon, Gregory A ^b   Walker, Paul R ^b   Quan, Francine M ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

famotidine; interleukin 2; kidney cancer; lymphokine activated killer cells; melanoma

Indexed keywords

CD56 ANTIGEN; FAMOTIDINE; INTERLEUKIN 2;

ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG PULSE THERAPY; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; KIDNEY CANCER; LYMPHOCYTE; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL;

ANTIGENS, CD56; FAMOTIDINE; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-2; KIDNEY NEOPLASMS; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTE COUNT; LYMPHOCYTES; MELANOMA;

EID: 79952137721     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2010.0879     Document Type: Article

References (13)

1. Grimm EA, Mazumder A, Zhang HZ, et al. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982;155:1823.
2. Ellis TM, Creekmore SP, McMannis JD, et al. Appearance and phenotypic characteristics of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin-2. Cancer Res 1988;48:6597.
3. McMannis JD, Fisher RI, Creekmore SP, et al. In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer pa-tients receiving recombinant IL-2. J Immunol 1988;140: 1335.
4. Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986;164:814.
5. Phillips JH, Gemlo BT, Myers WW, et al. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy. J Clin Oncol 1987;5:1933.
6. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994; 271:907.
7. Tsunoda T, Tanimura H, Yamaue H, et al. In vitro aug-mentation of the cytotoxic activity of peripheral blood mononuclear cells and tumor-infiltrating lymphocytes by famotidine in cancer patients. Int J Immunopharmacol 1992;14:75.
8. Quan WDY Jr., Walker PR, Picton M, et al. High dose in-tensity pulse interleukin-2 with famotidine has activity in metastatic melanoma. Cancer Biother Radiopharm 2008; 23:641.
9. Quan WDY Jr., Quan FM. High dose intensity pulse inter-leukin-2 with famotidine in metastatic kidney cancer. Cancer Biother Radiopharm 2009;24:181.
10. Quan WDY Jr., Knupp C, Quan FM, et al. Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma. Cancer Biother Radiopharm 2010;25:179.
11. Mitchell MS, Kempf RA, Harel W, et al. Low-dose cyclo-phosphamide and low-dose interleukin-2 for malignant melanoma. Bull N Y Acad Med 1989;65:128.
12. Harel W, Shau H, Hadley CG, et al. Increased lysis of mel-anoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro. Cancer Res 1990;50:6311.
13. Hersh EM, Murray JL, Hong WK, et al. Phase I study of cancer therapy with recombinant interleukin-2 administered by intravenous bolus injection. Biotherapy 1989;1:215.